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ABSTRACT
Osteogenesis imperfecta (OI) is a heritable form of bone fragility typically associated with a dominant COL1A1 or COL1A2 mutation.
Variable phenotype for OI patients with identical collagen mutations is well established, but phenotype variability is described using the
qualitative Sillence classification. Patterning a new OI mouse model on a specific collagen mutation therefore has been hindered by the
absence of an appropriate kindred with extensive quantitative phenotype data. We benefited from the large sibships of the Old Order
Amish (OOA) to define a wide range of OI phenotypes in 64 individuals with the identical COL1A2 mutation. Stratification of carrier spine
(L1–4) areal bone mineral density (aBMD) Z-scores demonstrated that 73% had moderate to severe disease (less than  2), 23% had mild
disease ( 1t o 2), and 4% were in the unaffected range (greater than  1). A line of knock-in mice was patterned on the OOA mutation.
Bone phenotype was evaluated in four F1 lines of knock-in mice that each shared approximately 50% of their genetic background.
Consistent with the human pedigree, these mice had reduced body mass, aBMD, and bone strength. Whole-bone fracture susceptibility
was influenced by individual genomic factors that were reflected in size, shape, and possibly bone metabolic regulation. The results
indicate that the G610C OI (Amish) knock-in mouse is a novel translational model to identify modifying genes that influence phenotype
and for testing potential therapies for OI.  2010 American Society for Bone and Mineral Research.
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Introduction
O
steogenesis imperfecta (OI) is a heritable form of bone
fragility with an overall spectrum of disease severity that
ranges from a perinatal lethal form to mild disease that can
remain clinically silent.
(1–3) Multiple fractures is the principal
clinical presentation that brings OI patients to medical attention.
Additional phenotype traits can include bone deformity (e.g.,
long bone bowing), short stature, blue sclerae, dentinogenesis
imperfecta (DI), and hearing loss. Sillence originally classified OI
into types I to IV on the basis of clinical presentation,
radiographic features, and mode of inheritance.
(4,5) OI types I
to IV typically are associated with heterozygous mutations in the
genes (COL1A1 and COL1A2) that encode the a chains of type I
procollagen molecules. Currently, more than 800 COL1A1 and
COL1A2mutationshavebeenidentifiedinOIpatients,withmany
examples of recurrent mutations in unrelated individuals.
(3)
However, there are no large pedigrees with quantitative
phenotype data for OI patients with the identical mutation.
The predominant type I collagen isotype in the extracellular
matrix (ECM) is a heterotrimeric molecule comprised of two a1(I)
chains and one a2(I) chain. A homotrimeric isotype of type I
collagen, comprised of three a1(I) chains, is also found in tissues
in small amounts in the nonpathologic state. The homotrimeric
isotype is associated with autosomal recessive connective tissue
disorders in humans when no a2(I) chains or only nonfunctional
a2(I) chains are synthesized.
(6,7) The amino acid sequences of
both a1(I) and a2(I) chains are homologous and have a
characteristic [Gly-X-Y]338 repeat within their respective triple-
helical domains. The small side chains of glycine residues
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247positioned at every third position of the repeat are sterically
required for helix formation, and mutations in these glycine
residues account for 80% of the known triple-helical mutations
that cause moderately severe to lethal forms of OI.
Over the past two decades, several laboratories have
developed murine OI models based on mutations in the proa1(I)
chain of type I collagen patterned after those described in
human OI to extend our understanding of OI pathobiology. All
the existing mouse models have a moderate-to-severe bone
phenotype with impaired viability. The two early models of note
are the Col1a1 null allele Mov-13 mice
(8–10) and the ‘‘protein
suicide’’ or collagen minigene model.
(11–13) The homozygous
Mov-13 mouse produces no type I collagen, and this is lethal.
Heterozygous Mov-13 mice deposit reduced amounts of normal
type I collagen in the ECM that is associated with an osteopenic
phenotype and abnormal skeletal biomechanics. The minigene
model construct expresses a version of the human COL1A1 gene
that is missing the central 41 exons that encode a significant
portion of the triple-helical domain. The shortened human
proa1(I) chains associate with normal murine proa1(I) and
proa2(I) chains, depleting the amount of normal type I collagen
and altering ECM organization. Most recently, the Cre/lox
recombination system was used to develop a Col1a1 G349C
substitution to reproduce a human OI type IV (moderately
severe) phenotype termed BrtlIV.
(14–17) The BrtlIV mouse
represented a major advance in OI mouse models because it
is the only Col1a1 model with a triple-helical glycine mutation.
The OI phenotype pattern of proa2(I) glycine substitutions
appears to be different from proa1(I) substitution.
(3) Generally,
proa2(I) mutations are less severe. They also may represent
an easier target for treatment because only 50% of collagen
molecules are affected in COL1A2 heterozygotes versus 75% in
COL1A1 heterozygotes. However, the only reported mouse
model for OI with a Col1a2 mutation is osteogenesis imperfecta-
murine(oim).Homozygousoimmiceexhibitskeletaldiseasewith
clinical and biochemical features of Sillence type III (severe
progressive) OI. The oim mutation and its biologic conse-
quences
(18–21) are strikingly similar to those found in a German
child with type III OI.
(6,22,23) In both instances, a frame-shift
mutation in the region of the COL1A2 gene that encodes the
terminal portion of the proa2(I) C-propeptide predicts the
synthesis of nonfunctional proa2(I) chains. Despite being the
only naturally occurring OI mouse model, the oim mouse has a
rarely observed type of mutation and an atypical biochemical
phenotype because only proa1(I)3 homotrimeric molecules are
formed.
The absence of a COL1A2 murine OI model with autosomal
dominant inheritance, mild to moderate disease, and phenotype
variation represents a major gap in our tools to understand OI
pathobiology and to develop effective treatment. Defining the
molecular basis of phenotype variation also has been limited by
the absence of large numbers of OI patients carrying the
identicalcausativemutationwithquantitativephenotypedatato
useas aprototype foranewOI mousemodel.Here wereport the
clinical and biochemical phenotype of a COL1A2 gene variant
found among a Lancaster County, Pennsylvania, Old Order
Amish (OOA) kindred. This COL1A2 variant is a G-to-T
transversion at nucleotide 2098 that alters the gly-610 codon
(GGT) toacysteine(TGT) codon.
(24) Wealsoreport the creation of
the first glycine-substitution knock-in Col1a2 mouse that
replicates the gene and protein phenotypes observed in the
OOA kindred. The knock-in G610C OI (Amish) mouse represents a
unique translational model for evaluating the molecular basis of
phenotype variability and to test potential therapeutic strategies
for OI.
Materials and Methods
Ethical considerations
All human subject research was reviewed and approved by the
Institutional Review Board of the University of Maryland
Baltimore (UMB). Informed consent was obtained for all study
participants. All animal procedures were reviewed and approved
by the UMB Institutional Animal Care and Use Committee.
Recruitment of family members and phenotype
assessment
The study had three stages of informed consent: (1) mutation
screening, (2) clinical assessment, and (3) skin-biopsy harvest.
The screening enrollment age requirement of 6 years or older
was waived if one parent was mutation-positive by sequence
analysis. After obtaining informed consent (or assent from the
children), buccal cells were harvested as a source of genomic
DNA (gDNA) for genotyping. All gDNA- and cDNA-derived
sequence data (see below) were analyzed, using Sequencher
software (GeneCodes, Ann Arbor, MI, USA).
All volunteers verified by gDNA sequence analysis to carry a
single copy of the T allele (OI group) and their control (G allele)
nuclear family members (age 6 years) were invited to
participate in the clinical assessment and skin-biopsy phases.
The phenotype assessment consisted of a medical and family
history, physical examination, blood draws for serum procolla-
gen type I C-terminal propeptide (PICP) and CrossLaps
measurements (markers of bone formation and resorption),
and measurement of areal bone mineral density (aBMD). Lumbar
spine (L1–4) and proximal femur (total and subregions) aBMD
was measured by dual-energy X-ray absorptiometry (DXA) on a
QDR 4500W instrument (Hologic, Bedford, MA, USA), and the
results reviewed by a single clinician (EAS) and another author
(DJM). The in vivo coefficient of variation for replicate aBMD
measurements was 0.8% for the lumbar spine, 0.9% for total hip,
and 1.5% for the femoral neck. The Hologic Pediatric Reference
Curve Option (hip: 5 to 20 years; spine: 3 to 20 years) and
Caucasian reference (age>20 years) were used to obtain age-
specific Z-scores. Since OI is frequently associated with short
stature and bone mineral content (BMC) and aBMD are
influenced by bone size, volumetric bone mass [bone mineral
apparent density (BMAD)] also was estimated to minimize the
influence of small bone size.
(25,26) A subset of the phenotype
assessment volunteers also provided 3mm dermal punch
biopsies from the posterior upper arm from which fibroblasts
were derived and stored at UMB and/or submitted to the Coriell
Institute (OI families 1997, 1998, 2187, and 2229).
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Knock-in mice were created using embryonic stem cells and Cre/
lox P technology. A 13kb genomic clone containing the relevant
segment of the murine Col1a2 gene was isolated from a l phage
library constructed with gDNA of the 129Sv/Ev Taconic mouse
strain. PCR site-directed mutagenesis was used to change the
targeted codon from GGT to TGT. The Col1a2 G610C-positive
embryonic stem cells were injected into blastocysts of C57BL/6J
(B6) mice. Founder mice that retain the neo targeting vector are
termed neoþ or G610C Neo mice. Progeny obtained by breeding
a founder male with a female that expressed Cre recombinase
(JacksonLaboratory, BarHarbor, ME,USA,StockNumber003724)
are termed neo– or G610C OI mice. The G610C OI mouse line is
available to the research community through the Jackson
Laboratory Mouse Repository (Jax Stock Number: 007248).
Four F1 strains of G610C OI mice were used to determine the
effect of genetic background on phenotype in 2-month-old male
mice. Incipient congenic G610C OI B6 ( 98% B6 genetic
background) male breeders were generated by six generations
of backcrosses to Jackson Laboratory B6 mice (Stock Number
000664). Experimental heterozygous B6 male breeders were
crossed with A/J (Stock Number 000646), BALB/cByJ (Stock
Number 001026), C3H/HeJ (Stock Number 000659), and FVB/NJ
(Stock Number 001806) females purchased from the Jackson
Laboratory. Progeny of these crosses are designated, respec-
tively, as A.B6, Cby.B6, C3.B6, and FVB.B6. Experimental mice were
housed atUMB inasinglespecific-pathogen-free room andwere
exposed to identical environmental conditions consisting of a 12
hour light/dark cycle, an ambient temperature of 238C, and
adlibitumaccesstowaterandlaboratorymousechow.Genotype
was assigned using a PCR assay that can discriminate the three
possible G610C OI mouse genotypes. The forward primer (TCC
CTG CTTGCC CTA GTC CCAAAGATC CTT)and the reverse primer
(AAG GTA TAG ATC AGA CAG CTG GCA CAT CCA) will generate a
165bp (wild type) or a 337 and a 165bp (heterozygous) or a
337bp (homozygous) PCR product using G610C OI mice gDNA.
All animals were euthanized by CO2 asphyxiation.
Human and mouse collagen analysis
Pepsin-soluble collagen was purified from mouse tail tendons
and human fibroblast culture medium for analysis by SDS-PAGE
and differential scanning calorimetry (DSC). Purified collagen
samples were labeled by fluorescent monoreactive Cy5 NHS
ester (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA) or
double-labeled by Cy5 and fluorescent BODIPY-L-Cys (Molecular
Probes, Invitrogen, Inc., Carlsbad, CA, USA).
(27) Labeled proteins
were size-separated by SDS/PAGE on precast 3% to 8% gradient
Tris-acetate minigels (Invitrogen). Following electrophoresis, the
gels were briefly rinsed in distilled water and scanned on a Fuji
FLA5000 fluorescence scanner (Fuji Medical Systems, Stamford,
CT, USA) using a 473nm excitation laser for BODIPY-L-Cys and a
635nm laser for Cy5. For DSC, collagen was redissolved (1 to
2mg/mL final collagen concentration) in 2mM HCl (pH 2.7) or in
0.2M sodium phosphate/0.5M glycerol (pH 7.5) and then
dialyzed extensively against the same buffer to remove excess
salt.DSCthermograms
(28)ofapproximately0.1mg/mLofpepsin-
treated collagen in 2mM HCl (pH 2.7) and in the phosphate/
glycerol buffer (pH 7.5) were recorded in a Nano II differential
scanning calorimeter (Calorimetry Sciences Corp. Lindon, UT,
USA) at several different scanning rates. The apparent melting
temperature Tm was defined at the maximum of the melting
peak after baseline subtraction.
Total RNA was extracted from fibroblast cultures, and cDNA
was synthesized using RACE1 [50-GAT GGA TCC TGC AGA AGC
(T)17-30]. An aliquot of cDNA and forward exon primer and
downstream reverse exon primer (selected to cross intron-exon)
boundaries were used for second-strand synthesis and PCR
amplification. PCR products of the expected size were confirmed
by agarose gel size separation prior to purification for direct
nucleotide sequencing.
Phenotype assessment of F1 G610C OI Mice
aBMD measurements
The aBMDs of right femurs were measured by DXA (GE-Lunar
densitometer, PIXImus; software version; 2.10, GE Medical
Systems, WI, USA). Femur measurements were obtained by
placing an excised femur on a Delrin block. The percent
coefficient of variation (CV) was 1.3% for BMC and 1.4% for BMD.
Confocal Raman microspectroscopy
Segments of cortical bone from the femur diaphysis were
embeddedinCryo-gel(Instrumedics,Inc.,St.Louis,MO,OSA)and
cut longitudinally normal to the bone surface on a Cryo-Cut One
cryostat (Vibratome, Bannockburn, IL, USA). The 30mm sections
were examined with a Senterra confocal Raman microscope
(Bruker Optics, Billerica, MA, USA). Raman spectra from 40 to
4500cm
 1 were collected with 9 to 18cm
 1 resolution using a
circularly polarized 20mW (9mW at the sample), 532nm laser
beam, X40/0.95 NA objective, and a 50mm confocal pinhole.
The spectra were acquired at 12 points visually selected outside
osteocytes along the periosteal toendosteal axis in the midplane
of the sections. The accumulation time for each point was
1 minute. The mineral content of bone matrix (PO4:CH), collagen
content of bone matrix (amide III:CH), and mineral:collagen ratio
(PO4:amide III) were determined from the areas under n1-PO4
(integrated from 901 to 987cm
 1), amide III (1214 to 1305cm
 1),
and CH (2824 to 3035cm
 1) Raman peaks. Relative collagen
content from Pro:CH ratio (833 to 867cm
 1) was consistent with
thatevaluatedfromtheamideIII:CHratiobutlessaccurateowing
to low intensity of the Pro peak.
Femur mCT
Micro-computed tomography (mCT) was used to quantify
femoral geometry, morphology, and mineralization (GE Medical
Systems, London, ON, Canada). Femurs from F1 male 2-month-
old mice were scanned over 200 degrees of rotation and
reconstructed on 18mm voxels. Cortical and trabecular analyses
included measures of bone mineral content and density, cortical
andtrabecularthickness,andtrabecularspacing.Corticalregions
of interest (ROIs) consisted of cylindrical segments (radius
1.35mm,height3mm)ofthemiddiaphyses.TrabecularROIsalso
consisted of cylindrical segments (radius 0.57mm, height equal
to 10% of total femur length) of the distal femoral metaphyses,
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to the cortical and trabecular ROIs (2000 and 1200 HU,
respectively).
Ex vivo mechanical testing
Femurs were mechanically tested at room temperature using a
four-point bending apparatus (858 Mini-Bionix, MTS, Eden
Prairie, MN, USA) in a manner described previously by Jepsen.
(10)
With posterior femoral surfaces kept in tension, displacement
was applied at 0.05mm/s. The upper and lower tines of the four-
point support were separated by 6.35 and 2.2mm, respectively.
Custom software was used to determine stiffness, yield, maxi-
mum load, and pre- and postyield fracture energy. Standard
beam theory was used to calculate yield stress and Young’s
modulus based on the mechanical testing data and femoral
geometry as measured by mCT.
Statistical analysis
Statistical analysis was performed using InStat and Prism
statistical software packages (Graphpad, La Jolla, CA, USA) or
SASstatisticalsoftware(SASInstitute,Cary,NC,USA).Atwo-tailed
p value of .05 or less for any single analysis was considered
statistically significant. Outliers (defined as values exceeding 
2s from the group mean) were removed from the mCT and four-
point bending data sets.
Results
OOA kindred genotyping/pedigree structure
Putative founder couple identification
A54-year-oldwomanwithahistoryoffracture, lowhipandspine
aBMD, and a differential diagnosis of idiopathic osteoporosis or
OI was identified in the Amish Family Osteoporosis Study
(AFOS).
(29,30) A brother and a niece of the woman also were
identified with a history of fracture and low aBMD. gDNA was
extracted from blood of the proband’s brother for analysis of
COL1A1 and COL1A2 genes.
(31–33) Nucleotide sequencing
identified a G-to-T substitution that converts the triple-helical
codon for glycine-610 (GGT) to cysteine (TGT). Sequence analysis
confirmed that the proband, brother, and niece carried a single
copy of the mutant T allele. Three additional AFOS DNA samples
(a grandmother, mother, and granddaughter) were found
subsequently to carry single copies of the variant T allele.
The Anabaptist Genealogy Database (AGDB4)
(34,35) was
queried using PedHunter
(36) software to link the six individuals
withthemutantT alleletoaputativefoundercouple(Fig.1)born
approximately 150 years ago. AGDB genealogic records listed
approximately 1200 descendents from four of the putative
founder couple’s children, of which approximately 800 are
estimated to be alive today. Genotype status was obtained for
195 study participants; 149 were direct descendants of the
putative founder couple, 19 were direct-descendant married-in
spouses, and 27 were descendants of the putative founder
couple’ssiblingsormoredistantrelatives.ThevariantTallelewas
identified in 64 descendants in 22 sibships ranging in age from
3weeksto86years.Sibshipsrangedfrom2to11individualswith
an average of approximately 6 individuals. The overall sibship
genotype distribution exhibited a normal Mendelian 1:1 ratio
expected for offspring from one carrier parent and one wild-type
parent. No homozygous individuals and no carrier carrier
couples were identified.
OOA kindred phenotype
Standing height
Standing height as a function of age (Fig. 2) suggested that OI
family members tended to be shorter than their unaffected
family members. Standing height was converted to Z-scores to
better assess the effect of the T allele across the wide age
range of study participants. OOA-specific standing height
Z-scores were generated separately for women and men from
height data obtained from 1687 females and 1416 males
(age>20 years) enrolled in non-OI research studies (unpub-
lished UMB data). Since OOA-specific data were unavailable for
study participants 6 to 20 years of age, standing height Z-scores
were generated using the National Health and Nutrition
Examination Survey (NHAHES) data (https://web.emmes.com/
study/ped/resources/htwtcalc.htm). Mean standing height Z-score
was significantly less (p<.001) for carriers of the T allele as
compared with control family members but with appreciable
overlap in Z-scores between control and OI study participants
(see Fig. 2).
Biomarker measurements
PICP values for OI family members were relatively constant as a
function of age (see Fig. 2). However, PICP for control family
Fig. 1. OOA COL1A2 G610C putative founder couple pedigree. The
COL1A2 variant is a G-to-T transversion at nucleotide 2098 that alters
the gly-610 codon (GGT) to a cysteine (TGT) codon. The mutant T allele
has been mapped in 64 heterozygous descendants of the putative
founder couple born approximately 150 years ago. Four of the founder
couple’s offspring have an estimated 800 living descendants, whereas
the other five offspring produced no progeny. (Control genotype¼GG;
OI genotype¼GT.)
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compared with OI family members. Genotype (p<.0001) and
age (p<.0086) were found tomakesignificant contributions ina
multiple regression model using age, sex, and genotype as
variables for PICP. In contrast, only age (p<.0001) was found to
make a significant contribution to serum CrossLaps.
BMD measurements
Lumbar spine (L1–4) and femoral neck (FN) BMAD by age shown
for males and females suggested that the OI group has reduced
BMAD compared with family controls. Age, sex, genotype, and
weight were used as predictor variables in multiple regression
models for lumbar spine and FN BMAD. Sex (p<.03) and
genotype (p<.0001) made significant contributions to lumbar
spine and FN BMAD. Weight (p<.0001) also contributed to
lumbar spine BMAD, and age (p<.0001) contributed to FN
BMAD.BMD assessedasZ-scoresforthe spineandhipareshown
in Fig. 3. Mean Z-score differences between the OI and control
groups at the lumbar spine and the FN were significant
(p<.0001). The mean Z-score at the lumbar spine was
 2.63 0.99 for the OI group and  0.24 0.82 for the control
group. Mean FN Z-scores were  1.18 0.91 for the OI group and
0.26 0.78 for the control group.
Production of the knock-in mice
Nucleotide gDNA sequence (GenBank Accession Identifier
DQ377843) analysis demonstrated that F1 founder mice
(male¼1, female¼2) were heterozygous for the knock-in
mutationinCola2exon33(equivalenttoCOL1A2exon35).Intron
32 for the F1 founder knock-in allele [Col1a2
tm1Mcbr; Mouse
Genome Informatics (MGI) ID 3805459] contains 2712 nucleo-
tides, whereas the wild-type B6 allele contains 730
nucleotides. F1 founder mice cDNA sequence analysis confirmed
expression of mutant and wild-type mRNA. Offspring carrying
one or two copies of the knock-in Col1a2
tm1Mcbr allele from F1
founder breeding survived without any detectable lethality at
birth or beyond weaning and were fertile.
Genomic DNA sequence analysis confirmed the Cre-mediated
excision of the Floxed neo cassette in an F2 male mouse that was
subsequently used to sire G610C OI mice progeny on a B6
background. Intron 33 in G610C OI mice is comprised of 852
nucleotides, and its MGI allele designation is Col1a2
tm1.1Mcbr (MGI
Accession Identifier 3711122). It differs in size from the wild-type
B6 sequence by the addition of 144bp of residual targeting
vector sequence that flanked the lox P sites and the loss of 22bp
of B6 sequence (GenBank Accession Identifier DQ377844).
Heterozygous wild-type breeding produced litters with both
expected genotypes. However, no viable homozygous offspring
were obtained from heterozygous matings. Genotype analysis of
dead pups recovered within 24 hours of birth did demonstrate
thepresenceofpupshomozygousfortheCol1a2
tm1.1Mcbrallelein
the litters.
Human and mouse SDS-PAGE analysis
Double labeling with Cy5 and Bodipy-L-Cys revealed intense Cys
staining of a2(I) chains from all mutant animals and proband
collagens(Fig.4A,B),indicatingthepresenceofexposedreactive
Cys-SH residues in a2(I) chains of type I collagen triple helices.
Interestingly, SDS-PAGE also revealed the presence of reducible
a2-Cys-S-S-Cys-a2 dimers in tendons of all mutant animals (see
Fig. 4C, D). Since type I collagen triple helix contains only one a2
Fig. 2. OOA kindred standing-height and serum biomarker measurements. Height (left four panels): Male (left) and female (right) carriers (GT) of the
COL1A2 G610C allele (OI) tend to have reduced standing height compared with control (GG) family members. Standing height Z-scores for individuals
younger than 20 years of age were calculated using NHANES normative data, whereas an OOA-specific Z-score was calculated for individuals older than
20 years of age. The mean OI Z-score for standing height was significantly reduced (p<.0001) compared with family controls for both age groups.
Biomarkers (right four panels): PICP (left) and CrossLaps (right) are serum biomarkers associated with collagen metabolism. PICP reflects collagen
biosynthesis in bone. PICP values exhibited variations with age and disease status. The participants heterozygous for the G610C COL1A2 allele (OI) who
were younger than 20 years of age exhibited significantly reduced PCIP as compared with normal control family members. CrossLaps levels reflect the
degradation of bone collagen and can be considered a surrogate for bone resorption. No obvious association with age or disease status was observed for
the CrossLaps data.
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The intermolecular dimers likely form prior to fibrillogenesis
because in the fibrils the Cys residues of adjacent triple helices
are axially separated by at least one D period. Dimer formation
likely occurs in the Golgi stack by nonspecific side-by-side
interactions of procollagen molecules. Surprisingly, the aberrant
intermolecular dimers are incorporated into the tissues of
mutant animals. From the intensities of the bands containing the
S-S dimers and corresponding bands without the dimers, the
estimated fraction of mutant chains involved in the dimers was
approximately 1% in heterozygous neoþ, approximately 1.5% in
heterozygousneo–,andapproximately9%inhomozygousneoþ
animals (Table 1).
SDS-PAGE analysis also demonstrated an abnormally high
ratio of a1(I):a2(I) fluorescence intensities in neoþ (Col1a2
tm1Mcbr
allele) animals, approximately 3:1 in heterozygous neoþ and
approximately 8:1 in homozygous neoþ versus approximately
2:1 in wild-type and heterozygous neo– (Col1a2
tm1.1Mcbr allele)
animals. Most likely this was caused by insufficient synthesis of
mutant a2(I) chains and formation of a1(I) homotrimers [e.g.,
owing to partial degradation and/or slower transcription,
splicing, and/or translation of the neoþ (Col1a2
tm1Mcbr) mRNA
containing the intron 33 targeting vector]. Based on this
assumption, we estimated the homotrimer content as approxi-
mately 23% and approximately 67% in tendons of heterozygous
and homozygous neoþ animals correspondingly (see Table 1).
Human and mouse DSC analysis
Previous differentail scanning calorimetry (DSC) studies showed
that the denaturation temperature Tm of type I collagen
homotrimers at acidic pH is approximately 2.58C higher than
that of normal heterotrimers.
(28,37) Thus, to test whether the high
a1(I):a2(I) ratio was consistent with homotrimer formation, we
performed DSC scans of collagen from all mouse tendons and
human fibroblast cultures in 2mM HCl (pH 2.7). Inaddition to the
denaturation peak of normal type I heterotrimers, the DSC
thermograms of collagen from neoþ animals (see Fig. 4E) did
reveal a low-temperature peak consistent with mutant hetero-
trimers and a high-temperature peak. The high-temperature
peak was identical to oim and artificial homotrimers measured at
the same conditions.
(28,38) This peak was absent in collagen from
neo– animals (see Fig. 4F) and from human proband fibroblasts
(see Fig. 4G). Deconvolution of the DSC thermograms suggested
approximately 24% and approximately 62% content of homo-
trimers in heterozygous and homozygous neoþ animals,
respectively, in agreement with SDS-PAGE.
To evaluate the effect of the G610C substitution on the
thermal stability of mutant collagen, we measured similar DSC
thermograms in 0.2M sodium phosphate and 0.5M glycerol (pH
7.5), which can be used to evaluate the Tm under physiologic
conditions by subtraction of 1.78C. From the buffer-corrected
thermograms (see Fig. 4H–J), we estimate that the incorporation
ofthemutanta2(I)chainresultsinaTmreductionby2.38Cinmouse
and approximately 18C in human collagens correspondingly.
F1 G610C OI mouse phenotype
Breeding
A total of 301 experimental mice were obtained from 48 litters.
Genotype was determined for the mice, except for one B6.Cby
female mouse. Mean litter sizes differed among the four F1 stains
(one-way ANOVA p¼.0039). The mean litter sizes were 7.9 1.9
(FVB.B6), 6.5 2.5 (Cby.B6), 5.0 2.2 (C3.B6), and 5.0 1.5 (A.B6).
Fig. 3. OOA kindred bone mineral density (DXA) measurements. The principal quantitative measure of phenotype severity was aBMD using DXA. BMAD
was calculated from L1–4 spine (A, B) and femoral neck (C, D) DXA aBMD measurements as an estimate of volumetric bone density. Both male (left) and
female (center) T allele individuals (OI) tended to have reduced BMAD compared with family controls as a function of age. Mean Z-scores using Hologic
normative date are reduced in OI family members as compared with controls in both the spine (E) and hip ( F).
252 Journal of Bone and Mineral Research DALEY ET AL.Goodness-of-fit testing indicated a significant deviation from
expected genotype ratios looking at data from all litters
(p¼.008). However, no individual strains had a significant
deviation from expected ratios.
Body weight
There wasa curvilinear relation between body weight (measured
longitudinally on days 21 to 60) and age (Fig. 5; age and age
squared both p<.0001). Wild-type animals were heavier than OI
animals (difference 1.77g, SE 0.3279, p<.0001). The A.B6 mice
had the lowest and the FVB.B6 mice had the greatest body
weight. FVB.B6 mice were significantly heavier than A.B6 mice
(difference 2.07g, p<.0001), FVB.B6 mice were significantly
heavier than Cby.B6 mive (difference 1.37g, p<.003 (both p
values adjusted for multiple comparisons using Tukey-Kramer).
There was no evidence of a strain-by-genotype interaction
(strain genotype p<.8).
Fig. 4. TypeIcollagenanalysis.TypeIcollagenfromhumanfibroblastculturesandfrommousetailtendonswasanalyzedbySDS-PAGE(A–D)andDSC(E–
J). G610C genotype status is represented as GG (control), GT (heterozygous), and TT (homozygous). Neoþ represents the Col1a2
tm1Mcbr allele in G610C
mice, and neo– represents the G610C OI mouse Col1a2
tm1.1Mcbr allele. The gels labeled by Cy5 and Bodipy-Cys are shown only in the Bodipy-Cys
fluorescence (A, B). The Cy5 fluorescence of these gels was used for identification of the bands and correction for nonspecific Bodipy-Cys labeling (the
residual nonspecific labeling still can be observed in the dimer bands). DTT was included in the sample loading buffer in panel (C) and excluded from the
sample buffer in panels(A), (B), and (D). Normalized DSC thermograms of purifiedpepsin-treated collagenfrom G610C (neoþ) andG610C OI (neo–) mouse
tail tendons and human fibroblasts were measured at pH 2.7 (2mM HCl; E–G) and pH 7.5 (measured in 0.2M sodium phosphate and 0.5M glycerol and
corrected by 1.78C to represent physiological conditions; H–J). Each peak represents the heat of denaturation of a distinct molecular form of type I
collagen. Relative areas under the peaks on each thermogram represent the fraction of the corresponding molecules in the mixture. The superscript m
identifies mutant a2(I) chains.
AMISH OI MUTATION Journal of Bone and Mineral Research 253aBMD of G610C OI mouse femurs
G610C OI mice had lower BMC (D¼0.005g, p<.001) and BMD
(D¼0.005g/cm
2, p¼.001). Mean aBMD rank order of the G610C
OI mice by maternal background strain for was A.B6<Cby.B6<
FVB.B6<C3.B6.PairwisecomparisonsoftheG610COImiceusing
the Scheffe multiple-comparisons adjustment procedure
resulted in a statistically significantly difference between
A.B6 OI and C3.B6 OI (D¼0.007g/cm
2, p¼.0061). A strain-by-
genotype interaction was not significant for either BMC or BMD
(p .9).
Confocal Raman microspectroscopy
Mineral content of bone matrix (PO4:CH) (Fig. 6) was found to be
affected by genotype (p<.0001) and mouse strain (p¼.009). A
significant curvilinear relationship was observed between
mineral content and bone location (p¼.0065). The miner-
al:collagen ratio (PO4:amideIII) also was found to have a
significant genotype (p<.0001) effect and a curvilinear relation-
ship between mineral content and location (p¼.047) but no
evidence of a strain effect (p¼.36). The curvilinear relationships
for PO4:CH and PO4:amideIII had peak values located around the
middle of the cortical bone. Only genotype was found to have a
significant (p<.0001) effect for the collagen content of bone
matrix (amideIII:CH). Mouse strain-by-genotype interaction was
not significant for any of the Raman data.
mCT
Table 2 shows mean values of selected trabecular and cortical
bone parameters obtained from isolated femora. Cortical shape
and femur length were qualitatively very similar for each
Table 1. Differential Scanning Calorimetry (DSC) and SDS-PAGE Analysis of Type I Collagen
Sample Genotype
DSC SDS-PAGE
a12a2, % a12a2
m,%
a a13,% a13, % Reactive Cys-SH a2
m–S–S–a2
m,%
a
Mouse GG 100 0 0 0 0 0
Mouse neoþ GT 59 5
b 17 1
b 24 5
b 23 5 Yes 1 0.3
Mouse neoþ TT 0 38 1
b 62 1
b 67 5 Yes 9 3
Mouse Neo– GT 51 1
b 49 1
b 0 0 Yes 1.5 0.3
Human GG 100 0 0 0 No —
Human GT 50 10
b 50 10
b 0 0 Yes —
aThe superscript m identifies mutant chains.
bEstimated deconvolution error.
Fig. 5. F1 G610C OI mouse growth curves. Body-weight curves demonstrated a curvilinear relation between weight and age for all groups of mice. Strain
and genotype were independent predictors of weight. The wild-type (control; black squares) mice were 1.77g heavier than the OI mice (heterozygous for
the Col1a2
tm1.1Mcbr allele; gray diamonds), with the greatest difference in body weight between the FVB.B6 and the A.B6 groups.
254 Journal of Bone and Mineral Research DALEY ET AL.background strain control-OI pair (data not shown). Overall, the
mCT trabecular and cortical data show that all G610C OI mice
carrying one copy of the Col1a2
tm1.1Mcbr allele had less bone as
measured by bone volume fraction. The trabecular bone was
distinguished by fewer and more widely spaced trabeculae.
Except for the FVB.B6 mice, the mean cortical thickness and area
were reduced by the presence of the Col1a2
tm1.1Mcbr allele. The
FVB.B6 control and OIgroupshad similarmeanvalues forcortical
thickness and area. All the OI femurs had reduced moment of
inertia (Iyy) compared with age-matched genetic background
controls. The cortical volumetric tissue mineral content (vTMC)
was lower in all OI mice relative to their genetic background
controls, except for the FVB.B6 OI group, which was the same as
the FVB.B6 control group. The cortical volumetric tissue mineral
density (vTMD) was elevated in all mice carrying Col1a2
tm1.1Mcbr
allele relative to their genetic background controls. The
trabecular vTMD was statistically the same for each genetic
background pair.
Four-point bending biomechanics
Isolated femurs were loaded to failure in a four-point bend-
testing apparatus to assess the impact of a single copy of the
Col1a2
tm1.1Mcbr allele and the role of genetic background on the
structural phenotype (Table 3). Specifically, femurs from mice
with one copy of the variant allele were significantly weaker and
more brittle than femurs from control mice. In addition, a
genotype-by-genetic-background (strain) interaction was sig-
nificant for failure load, stiffness, postyield ultimate displace-
ment, and energy to failure. The presence of the Col1a2
tm1.1Mcbr
allele resulted in a striking reduction in failure load for all F1 OI
mice compared with their strain-specific controls. The mean
failure load range was greater for control mice (24N for A.B6
mice to 35N for C3.B6) compared with OI mice (15N for A.B6
mice to 18N for C3.B6 mice). The impact of the Col1a2
tm1.1Mcbr
allele on the magnitude of the intrastrain control-OI difference in
stiffness was variable. The greatest intrastrain OI-control mean
difference was found in the C3.B6 group, where the
Col1a2
tm1.1Mcbr allele was associated with a 71% reduction in
mean stiffness. The OI mice in the other three groups had mean
stiffness values of 82% (A.B6), 91% (Cby.B6), and 98% (FVb.B6) of
their intrastrain controls. Mean values for postyield ultimate
displacement for OI mice were 45% (Cby.B6), 52% (C3.B6), and
59% (FVB.B6) of strain-matched control values. However, the
meanvalue forA.B6OImicewas95%ofthe controlvalue.Failure
energyrangedfrom0.78(Cby.B6)to1.14N-mm(C3.B6)fortheOI
mice and from 3.11 (A.B6) to 6.3 N-mm (FVB.B6) for controls.
Ultimate stress and Young’s modulus had statistically
significant genotype and strain differences, but the genotype-
by-genetic-background interaction was not significant (see
Table 3). Mean ultimate stress was reduced for all OI groups
relative to their genetic background controls and ranged from
67% (Cby.B6 OI mice) to 81% (C3.B6 OI mice). Young’s modulus
was increased across all OI groups carrying the Col1a2
tm1.1Mcbr
allele relative to their genetic background controls. The
magnitude of the mean Young’s modulus was not different
between OI-control pairs but varied by genetic background of
the strain.
Fig. 6. F1 G610C OI mouse Raman microspectroscopy. The collagen content of the OI (heterozygous for the Col1a2
tm1.1Mcbr allele) femurs was reduced
relative to wild-type (WT) control femurs, and the collagen was hypermineralized. A representative Raman spectrum illustrates the peaks used for data
analysis(upperleft), andcomparisonofchemical-specificratios in WT(blackbars) andG610COI (gray bars)femursdeterminedfromtheRamanspectra are
shown in the balance of the figure.
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The ascertainment of 64 related individuals harboring the
mutant T allele represents the largest reported collection of OI
patients with an identical collagen mutation. Amino acid
substitutions at invariant glycine residues typically result in
clinically apparent phenotypes and make ascertainment more
likely. While the original brother-sister-niece proband cluster
presented with some of the most severe clinical signs and
symptoms of OI in this kindred, our overall clinical data support a
Sillence type I (mild) to type IV (moderate) phenotype range.
Pedigree analysis suggests that the T allele was a de novo
mutation that occurred in the putative founder couple born circa
1860. The rapid OOA population growth from approximately 600
individuals in 1860 to about 31,000 children and adults today,
(39)
combined with stochastic events, endogamy, and large sibships,
likely contributed to the mutation’s expansion within the
Lancaster Settlement.
Fracture history is the most relevant phenotypic trait used to
make a clinical diagnosis of OI and to classify disease severity.
However, since radiographic and medical record documentation
of fractures were unavailable in the OOA kindred, the use of
fracture history was problematic in defining the range of
phenotypic severity associated with the T allele. The self-
reported fracture number (not shown), nevertheless, indicated
that the OI group was more prone to fracture and reinforced a
clinical diagnosis of OI. Instead, DXA measurements of aBMD
wereusedasacontinuous quantitativetraittoassessphenotypic
severity that reflected the Sillence OI type clinical spectrum. Prior
work suggests that mean aBMD for children and adults with OI
types III and IV is significantly reduced compared with controls,
but a significant number of OI type I patients had aBMD values
within the reference range.
(40–42) Non-OOA OI patients often
have L1–4 spine Z-scores in the  1t o 2 range for type I OI and
the  2t o 4 range for type IV OI patients (JCM clinical
experience). These stratification ranges demonstrate that the T
allele was associated with a wide range of disease severity
(Table 4) in the spine and a milder phenotype in the hip.
Skeletal growth deficiency is acardinal secondary feature of OI
that is reflected in the standing-height measurement. Type I OI
patients typically attain a subnormal to normal adult height,
whereas type IVOI patients, with a greater propensity for fragility
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Table 4. DXA Z-Score Stratification
Sillence
classification
a
Z-score
range
Spine
(L1–4)
Femoral neck
(FN)
Control
(GG)
OI
(GT)
Control
(GG)
OI
(GT)
Normal >  1 31 2 39 16
Type I  1t o 2 9 11 1 22
Type IV  2t o 403 2 0 8
Type III–IV <  4 0300
Total number 40 48 40 46
aStratificationbySillencetypeisbasedonclinicalexperience(JCM)with
non-OOA OI patients,
AMISH OI MUTATION Journal of Bone and Mineral Research 257fracture, have a shorter final standing height in the range of
pubertal children.
(43) Figure 2 demonstrates a consistent
reduction in standing height of T allele carriers compared with
kindred controls (mean Z-score difference of approximately 1.8
in both the <20- and >20-year-old groups). During childhood
and adolescence, some 90% of skeletal mass is attained,
(44) and
peak stature normally is attained by approximately 20 years of
age. The cross-sectional serum biomarker data suggest impaired
skeletal accretion and linear bone growth in T allele carriers; PICP
levels were relatively flat across the entire age spectrum for T
allele carriers (see Fig. 3). In normal, healthy children, PICP levels
reflect collagen biosynthesis associated with skeletal growth and
are known to change significantly with age and pubertal
development stages.
(45–47) In contrast to the PICP estimates of
bone formation, bone resorption (serum CrossLaps) had similar
age and sex patterns for both the OI and control groups. This
suggests anuncoupling between bone formation andresorption
for the OI group during a major period of bone mass accretion
that favors a net decrease in bone mass.
The OOA kindred and the G610C OI mouse share the classic OI
features of dominant inheritance and a triple-helical glycine
substitution. The biomedical significance of this kindred is its
clinical and quantitative prototypic varied disease severity that is
further enhanced by its rich resource of phenotype data, DNA,
and fibroblast cell lines. However, repeated access to kindred
bone samples and other tissues for experimental uses are
unlikely,thusnecessitatingcreationoftheG610COImousetoaid
future studies. Establishing the validity of the G610C OI mice as
the first a2(I) glycine substitution model required the following
elements: (1) duplication of the codon change, (2) expression of
mutant proa2(I) transcript, (3) deposition of mutant protein in
the ECM, and (4) confirmation of a bone phenotype.
Our initial evaluation of founder (neoþ) mice and their
progeny carrying the Col1a2
tm1Mcbr allele demonstrated that the
G610 codon was altered as planned and the mutant transcript
was expressed. Surprisingly, these mice secreted a significant
fraction of type I collagen homotrimer in addition to G610C-
containing heterotrimeric collagen. The formation of homo-
trimers appeared related to intron 32 targeting vector retention
because it was not detected in human patients and neo– mice.
Therefore, G610C OI (or neo–) mice carrying the Col1a2
tm1.1Mcbr
allele actually model the human condition accurately at the
gene, transcript, and protein levels. However, the neoþ animals
are of interest and important to understand because G610C
(neoþ) mice carrying both one and two copies of the
Col1a2
tm1Mcbr allele were viable yet had a very mild phenotype
by torsional testing of femurs (data not shown). This altered
phenotype associated with production of homotrimers suggests
that some OI patients with a2(I) mutations may benefit from
treatmentsdesignedtoshiftthebalanceofthechainsynthesisto
favor homotrimer production.
Given that phenotype variation was a significant clinical
feature observed among the OOA kindred, the impact of the
genetic background on phenotype severity was tested in
G610C OI mice carrying the Col1a2
tm1.1Mcbr allele. Heterozy-
gous wild-type mouse crosses resulted in good reproductive
fitness that matched the reproductive fitness of the OOA kindred
andyieldedF1strainswithapproximately50%interstraingenetic
background identity. Interestingly, reproductive fitness of
heterozygous heterozygous B6 matings was poor because
trial matings failed to produce offspring homozygous for the
Col1a2
tm1.1Mcbr allele that survived beyond the perinatal period.
Growth curves (body weight) from weaning to 2 months of
age demonstrated impaired weight gain for all four F1 mouse
strains carrying the Col1a2
tm1.1Mcbr allelerelative totheir controls.
This is likely a generalizable effect in mice caused by type I
collagen gene mutations because it has been reported for the
Mov13, oim, and BrtlIV OI models. Body weight is a complex
quantitative trait,
(48) and different inbred mice are exemplified
by characteristic patterns of weight gain with time (MGI
Database). It is likely that the different growth curves reflect
the maternal contribution to the genetic background of the F1
mice because inbred mouse strains exhibit characteristic
patterns of weight gain with age.
Since the degree and nature of bone matrix mineralization
may be an important determinant of resistance to fracture,
whole-femur mineral mass in F1 mice was assessed by aBMD and
mCT measurements. PIXImus measurements (Fig. 7) demon-
strated that all strains of mice carrying the Col1a2
tm1.1Mcbr allele
had a reduction in aBMD compared with controls, and this is
consistent with DXA data from the OOA kindred. However, mCT
measurement of increased cortical vTMD (see Table 3) better
reflects the tissue effects of the variant Col1a2 allele. This
apparent contradiction is explained by the 2D nature of aBMD
estimated by DXA versus the 3D data obtained by mCT. The mCT
data suggest the G610C OI mice have reduced total tissue
mineral content but also have reduced total bone mass that
results in greater bone mineralization compared with control
mice. Hypermineraliztion at the level of collagen fibers was
confirmed by Raman microspectroscopy and is consistent with
higher mean mineralization density in OI patient bone samples
measured by backscattered electron imaging.
(49)
Structural integrity of femoral cortical bone was assessed
using four-point bending, which is an ex vivo surrogate in mice
for increased long bone fracture risk associated with OI. The
structural (failure load) and material property (ultimate stress)
measures of femur strength at 2 months of age demonstrated
that a single copy of the Col1a2
tm1.1Mcbr allele reduced
mechanical integrity regardless of genetic background. Key
Fig. 7. F1 G610C OI mouse DXA. OI mice demonstrated a reduction in
meanwhole-femoralBMCandaBMDrelativetotheirgeneticbackground
wild-type (WT) controls. The rank order of the OI (heterozygous for the
Col1a2
tm1.1Mcbr allele) mice by background strain for aBMD means was
A.B6<Cby.B6<FVB.B6J<C3.B6.
258 Journal of Bone and Mineral Research DALEY ET AL.contributors to the structural soundness of bone include
geometric parameters (i.e., size, shape) and inherent material
properties such as the molecular integrity, quantity and
organization of type I collagen, and degree and nature of
collagen mineralization. While the mineral content of bone
contributes substantially to its stiffness, collagen tends to
dominate the properties of the postyield region of the load-
deformation curve. It would appear from the yield energy:total
energy ratio that once the bone starts to break, the presence of
the mutated collagen offers less resistance to complete failure in
G610C OI mice. The failure of the abnormal collagen heterotimer
to ‘‘toughen’’ the bone is likely due to a structural and/or
organizational defect caused by the mutation and/or a general
reduction in the amount of collagen per unit volume of bone.
Our human and mouse findings of reduced DSC denaturation
temperature Tm suggest that the global molecular (structural)
stability of the mutant collagen heterotrimer is weakened. This
reduction in Tm is commonly associated with OI collagen
mutations, although there is no simple relationship between the
magnitudeofTmdecreaseandOIdiseaseseverity.Reducedbone
matrix collagen content (measured by Raman microspectro-
scopy) also appears to contribute to loss of femoral structural
integrity in G610C OI mice. The variations in the murine bone
biomechanical properties across the several experimental strains
used in this study (genotype-by-strain interactions) provide
additional insight about skeletal complications among human
patients. Theeffect ofthe mutation on the estimated bone tissue
properties was the same across all strains, each demonstrating
significant and similar reductions in inherent tissue integrity.
However, the magnitude of structural property alterations (such
as failure load) appears to be dependent on genetic background
(strain). Taken together, these results suggest that the effect of
the mutation on basic, inherent bone tissue integrity is similar in
all OOA kindred patients (reduced modulus and increased
brittleness). However, the consequence of the defect on whole-
bone fracture susceptibility is influenced by individual genomic
factors that are reflected in size, shape, and possibly bone
metabolic regulation.
Mouse models have the advantage over human samples of
tightcontrolofgeneticbackground andtheabilitytocircumvent
or minimize the role of environment on phenotype. The F1
G610C OI screening crosses were successful in demonstrating
that genetic background variation affected bone geometry and
structural property phenotype. We speculate that additional
backcrosses will further magnify interstrain phenotype differ-
ences and enhance the probability of identifying major genetic
modifiers using standard and novel backcross and intercross
genetic mapping tools with proven success in the detection of
human disease gene modifiers.
(48,50) Bone trait modifiers
identified in the G610C OI mouse likely will include Col1a1 or
Col1a2 mutation-specific modifiers, some that are generalizable
for many OI mutation loci, and others that overlap with genes
associated with common forms of osteoporosis. Quantitative
trait locus (QTL) investigation in the G610C OI mouse also likely
will confirm QTLs found in prior osteoporosis studies, thus
narrowing the critical QTL regions.
(51,52) The OOA OI kindred and
AFOS data then can be used to confirm both sets of genes—
those common to osteoporosis and those unique to Ol.
In summary, the OOA kindred is the largest known OI kindred
with an identical type I collagen defect and extensive phenotype
data. The triple-helical glycine substitution and dominant
inheritance pattern are prototypic for most reported cases of
OI. While all the affected individuals share the same mutation,
theyvariedwidelyinphenotype,asquantifiedbyaBMDZ-scores.
The G610C OI mouse, patterned on the OOA family, duplicates its
gene and protein profile. The magnitude of structural property
alterations owing to the mutation was dependent on genetic
background (strain). The bone geometry and structural property
gene genetic background interactions suggest that noncolla-
gen genes can modify the G610C OI mouse OI phenotype.
Overall, these results demonstrate that G610C OI mice represent
a unique translational OI model to define the complex genetic
architecture controlling phenotype and for testing of potential
therapeutic approaches and treatment strategies for OI.
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